Sustained Virologic Response in HCV Not Lower With Alcohol Use

Traditionally treatment for chronic hepatitis C virus (HCV) infection has been reserved for people who have abstained from alcohol—in some cases for as long as 12 months—largely due to concerns about adherence to treatment protocols, which stemmed from experience with previously used interferon-based regimens.

Advanced Liver Fibrosis Increases Risk of HCC Diagnosis

While it is well-understood that both nonalcoholic fatty liver disease (NAFLD) and hepatitis C virus (HCV) infection commonly result in hepatic fibrosis and might lead to cirrhosis, it has not been clear whether advanced fibrosis, determined by measurements of liver stiffness, increases the incidence of hepatocellular carcinoma in veterans.

No Link Between AMI, Two-Dose HBV Vaccine

The overall prevalence of chronic hepatitis B infection in the United States is estimated to be around 1.59 million That’s one of the reasons the DoD, which has required hepatitis B vaccination for new recruits for nearly 20 years, added the mandate for existing servicemembers to receive the vaccine in 2014.

An Interview with George Ioannou, MD, MS

The VA’s unparalleled success in treating and curing hepatitis C infections (HCV) in veterans changed the leading risk factors for hepatocellular carcinoma in the nation’s largest health care system.

Hepatitis C ‘Cure’ Doesn’t Always Prevent Hepatocellular Carcinoma Development

More than 100,000 VA patients have been cured of hepatitis C with direct-acting antiviral treatment. Even though HCV is the leading cause of hepatocellular carcinoma in the United States, curing the infection only reduces the risk; it doesn’t entirely eliminate it. That’s why the VA has continued with research to determine who is at greatest risk of HCC and is looking at expanding screening.